APA (7th ed.) Citation

Thompson, J., Kityo, C., Kambugu, A., Lugemwa, A., Mwebaze, R., Thomason, M. J., . . . Rooney, J. (2018). Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. The Lancet infectious diseases, 18(1), 47-57. https://doi.org/10.1016/S1473-3099(17)30630-8

Chicago Style (17th ed.) Citation

Thompson, Jennifer, et al. "Lopinavir Plus Nucleoside Reverse-transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-line Treatment of HIV (EARNEST): 144-week Follow-up Results from a Randomised Controlled Trial." The Lancet Infectious Diseases 18, no. 1 (2018): 47-57. https://doi.org/10.1016/S1473-3099(17)30630-8.

MLA (9th ed.) Citation

Thompson, Jennifer, et al. "Lopinavir Plus Nucleoside Reverse-transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-line Treatment of HIV (EARNEST): 144-week Follow-up Results from a Randomised Controlled Trial." The Lancet Infectious Diseases, vol. 18, no. 1, 2018, pp. 47-57, https://doi.org/10.1016/S1473-3099(17)30630-8.